Lennard is an accomplished Oxford University physician with a successful track record in delivering strategic national projects. He is currently leading on national projects to instigate a national advance of cancer vaccines.
Combing academic expertise with effective project management and the strongest background in healthcare, Lennard has made significant contributions in advancing projects for healthcare systems, industrial partners, government and those affected by cancer.
He has received numerous awards for his efforts, including the National ACP McElwain Prize for work during the pandemic, and the IAP’s 21 Outstanding Young Physicians award, given to individuals under the age of 40 who have made outstanding contributions to the field. He has a strong track record of academic achievements, with over 50 publications in the highest impact journals, including the Lancet and JAMA.
DPhil, MA (Cantab), BmBCh (Oxon)
Associate Professor- cancer vaccines | University of Oxford
- NHSE national clinical advisor on innovation
- Senior clinical advisor, Office for Life Sciences
- Honorary consultant in Medical Oncology, Oxford University Hospitals NHS Foundation Trust
- Scientific Lead, Independent SAGE
Lennard's modus operandi is to empower those involved in cancer care, science and research. He is particularly interested in laying the groundwork to set the United Kingdom to become a world leader in research for cancer vaccines by 2030. This advance will be achieved by following a similar path laid by Oxford teams during the coronavirus vaccine.
Through openness, acting with the highest level of integrity and humility, large groups of people could align around strategic projects like an advance of vaccines for cancer, building momentum and ultimately lay the path for project successes. Lennard is dedicated to utilise these approaches to partner and drive innovation, accelerate scientific developments and ultimately deliver real world results for those affected by cancer.
His work and research have been covered by the BBC, ITV, Daily Mail, Tortoise Media, and international news outlets. He is an excellent communicator, as illustrated in his role in IndieSAGE. He is incredibly positive and enthusiastic in forming bridges between academics, industry, patients, government and health system.
Lennard’s has several notable achievements, including as founder of the UK COVID Cancer Program, a unique population-scale programme that utilised data to safeguard cancer patients globally during the pandemic. Furthermore, within the UK Moonshot, he delivered the research and managed the successful scale-up of lateral flow coronavirus diagnostics across our nations. In his NHS role, breaking new records, he successfully embedded the NHS-Galleri trial into 70 hospitals, as senior operations lead. This assessed a new blood test for 50 types of cancer and randomised 140,000 patients in just 10.2 months. For immunocompromised patient groups, he co-founded the impactful Forgotten500k campaign.
Finally, to advance our global leadership in vaccine technology, he helped realise a new UK partnership with a leading cancer vaccine company. This transformed domestic Life Sciences capabilities, and established access to cancer vaccine trials for 10,000 patients across multiple tumour types and stages.
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).
Starkey T. et al, (2023), Scientific reports, 13
Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
Suribhatla R. et al, (2023), British journal of haematology, 201, 813 - 823
The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research.
Fittall M. et al, (2023), British journal of cancer, 128, 1977 - 1980
Safe prescribing in cancer patients during the COVID-19 pandemic: A new initiative from the UK Cancer Coronavirus Project (UKCCP) team.
Appanna N. et al, (2023), International journal of cancer, 152, 1275 - 1277
Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review.
Al Hajji Y. et al, (2022), British journal of cancer, 127, 1827 - 1836